Sarizotan

Summary

Sarizotan (CHEMBL220808) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including movement disorder and rett syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 348.4 Da · C22H21FN2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL220808
Name	Sarizotan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918388
Molecular formula	C22H21FN2O
Molecular weight	348.4
InChIKey	HKFMQJUJWSFOLY-OAQYLSRUSA-N

SMILES: C1CC2=CC=CC=C2O[C@H]1CNCC3=CC(=CN=C3)C4=CC=C(C=C4)F

IUPAC name: 1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl)-3-pyridinyl]methyl]methanamine

Also known as: EMD-77697, Sarizotan, SARIZOTAN

Parent form; salt/anhydrous children: CHEMBL2146110

Patent coverage: 443 distinct patent families (1,853 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,846 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P19327	8.65	Ki	2.24	nM	CHEMBL_ACT_1818590
P61169	7.72	Ki	19.05	nM	CHEMBL_ACT_1818633
HTR1A	7.11	EC50	77.62	nM	CHEMBL_ACT_1818655
P14842	5.67	Ki	2138	nM	CHEMBL_ACT_1818611

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
movement disorder	3	MONDO:0005395	EFO:0004280
Rett syndrome	2	MONDO:0010726	MONDO:0010726

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00105508	PHASE3	COMPLETED	Sarizotan HC1 in Patients With Parkinson’s Disease Suffering From Treatment-associated Dyskinesia
NCT00105521	PHASE3	COMPLETED	Sarizotan in Participants With Parkinson’s Disease Suffering From Treatment Associated Dyskinesia
NCT00310661	Not specified	TERMINATED	Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).